On January 21, 2022, Aziyo Biologics, Inc. entered into (i) a second amendment (the “Term Loan Amendment”) to its Amended and Restated Credit and Security Agreement (Term Loan), dated as of July 15, 2019, by and among the Company, Aziyo Med, LLC (together with the Company, the “Borrowers”), MidCap Financial Trust and the other financial institutions or entities from time to time party thereto, as amended (the “Term Loan Credit Agreement”) and (ii) a second amendment (the “Revolving Loan Amendment” and, together with the Term Loan Amendment, the “Amendments”) to its Amended and Restated Credit and Security Agreement (Revolving Loan), dated as of July 15, 2019, by and among the Borrowers, MidCap Funding IV Trust (the “Revolving Agent”) and the other financial institutions or entities from time to time party thereto (together with the Revolving Agent, the “Revolving Lenders”), as amended (the “Revolving Loan Credit Agreement” and, together with the Term Loan Credit Agreement, the “Credit Agreements”). Under the terms of the Term Loan Amendment, the provision governing prepayment fees under the Term Loan Credit Agreement was amended such that any prepayment by the Company would require the payment by the Company of a prepayment fee equal to the amount prepaid (or required to be prepaid, if such amount is greater) multiplied by, in the case of each of Term Loan Tranche 1, Term Loan Tranche 2, Term Loan Tranche 3, Term Loan Tranche 4 and Term Loan Tranche 5 (each as defined in the Term Loan Credit Agreement), 3.0% until January 21, 2023 and 2.0% thereafter. Under the terms of the Revolving Loan Amendment, the provision governing deferred revolving loan origination fees under the Revolving Loan Credit Agreement was amended such that any termination or permanent reduction in the Revolving Lenders' funding obligations in respect of the Revolving Loan Commitment (as defined in the Revolving Loan Credit Agreement) prior to the Maturity Date (as defined in the Revolving Loan Credit Agreement), would require the payment by the Company of deferred revolving loan origination fee equal to the amount of the Revolving Loan Commitment so terminated or permanently reduced multiplied by 3.0% until January 21, 2023 and 2.0% thereafter.